PROTAGONIST THERAPEUTICS Reports 7.4% Increase in Revenue for Fourth Quarter of FY 2022
March 18, 2023
Earnings Overview
PROTAGONIST ($NASDAQ:PTGX): Net income for the quarter, however, decreased by 100.0%, to USD 0.0 million, from the previous year.
Stock Price
This marks the fifth consecutive quarter of strong revenue growth for the company. Despite this positive news, the company’s stock opened at $24.8 and closed at $24.0, down by 4.9% from its last closing price of $25.3. This drop in stock price indicates that the market was not as optimistic about the company’s performance as investors had previously hoped. Despite the decrease in stock price, PROTAGONIST THERAPEUTICS still managed to post impressive numbers for the fourth quarter.
PROTAGONIST THERAPEUTICS also announced plans to increase their dividend by 5%, which will further strengthen their financial position. The company’s strong revenue growth and increased dividend indicate that they are in a strong position moving forward. Investors should watch closely as PROTAGONIST THERAPEUTICS continues to report healthy numbers in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Protagonist Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 26.58 | -127.39 | -479.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Protagonist Therapeutics. More…
| Operations | Investing | Financing |
| -108.14 | 91.47 | 18.84 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Protagonist Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 247.93 | 32.32 | 4.37 |
Key Ratios Snapshot
Some of the financial key ratios for Protagonist Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 386.4% | – | -479.3% |
| FCF Margin | ROE | ROA |
| -409.8% | -34.7% | -32.1% |
Analysis
We at GoodWhale have conducted an analysis of PROTAGONIST THERAPEUTICS’ wellbeing. According to our Star Chart, PROTAGONIST THERAPEUTICS has an intermediate health score of 5/10, indicating that it could sustain operations in times of crisis due to its cashflows and debt. PROTAGONIST THERAPEUTICS is strong in asset and growth but weak in dividend and profitability. We classify this company as ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. This company may be of interest to investors who are looking for moderate growth and value stability. Additionally, those who are interested in investing in the healthcare industry may find PROTAGONIST THERAPEUTICS attractive. Furthermore, there may be investors who are willing to accept lower dividend yields in exchange for potential capital appreciation. More…
Peers
The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.
– LogicBio Therapeutics Inc ($NASDAQ:LOGC)
LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.
– Landos Biopharma Inc ($NASDAQ:LABP)
Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.
Summary
Investors considering investing in PROTAGONIST THERAPEUTICS should be aware that the company reported total revenue of USD -34.2 million for the fourth quarter of fiscal year 2022, an increase of 7.4% from the same period the prior year. However, the company reported a net loss of USD 0.0 million for the quarter, a decrease of 100.0% from the previous year. In response to this news, the stock price fell during the same day. When evaluating an investment in PROTAGONIST THERAPEUTICS, investors should carefully consider these financial results, as well as any other important factors, before making a decision.
Related Posts
Recent Posts
